Mark A. Kay
Direktor/Vorstandsmitglied bei Genevant Sciences Corp.
Profil
Mark A.
Kay is the founder of Voyager Therapeutics, Inc. (2013), American Society of Gene & Cell Therapy (2005), and LogicBio Therapeutics, Inc. (2014).
He held the title of President at American Society of Gene & Cell Therapy from 2005 to 2006 and the title of Independent Director at LogicBio Therapeutics, Inc. from 2016 to 2022.
Currently, he is an Independent Director at Genevant Sciences Corp.
since 2018 and a Professor & Head-Human Gene Therapy Division at Stanford University School of Medicine since 1998.
Dr. Kay received his undergraduate degree from Michigan State University and his doctorate from Case Western Reserve University.
Aktive Positionen von Mark A. Kay
| Unternehmen | Position | Beginn |
|---|---|---|
| Stanford University School of Medicine | Corporate Officer/Principal | 01.01.1998 |
Genevant Sciences Corp.
 Genevant Sciences Corp. Pharmaceuticals: MajorHealth Technology Part of Roivant Sciences Ltd., Genevant Sciences Corp. operates as a Canadian biopharmaceutical company. The company is based in Burnaby, Canada. The CEO of the company is Bo Rode Hansen. | Direktor/Vorstandsmitglied | 19.11.2018 |
Ehemalige bekannte Positionen von Mark A. Kay
| Unternehmen | Position | Ende |
|---|---|---|
| LOGICBIO THERAPEUTICS, INC. | Gründer | 16.11.2022 |
American Society of Gene & Cell Therapy
 American Society of Gene & Cell Therapy Miscellaneous Commercial ServicesCommercial Services The American Society of Gene & Cell Therapy is a medical and professional organization that represents researchers and scientists devoted to the discovery of gene and cell therapies. The American company was founded by Mark A. Kay. | Gründer | 01.01.2006 |
| VOYAGER THERAPEUTICS, INC. | Gründer | - |
Ausbildung von Mark A. Kay
| Michigan State University | Undergraduate Degree |
| Case Western Reserve University | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| VOYAGER THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 3 |
|---|---|
LogicBio Therapeutics, Inc.
 LogicBio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology LogicBio Therapeutics, Inc. engages in the development of a genome editing technology platform. It focuses on the commercialization of GeneRide, which enables the site-specific integration of a therapeutic transgene without nucleases or exogenous promoters by harnessing the native process of homologous recombination. Its pipeline includes LB-001, LB-301 and LB-401. The company was founded by Mark A. Kay, Leszek Lisowski, and Adi Barzel in August 2014 and is headquartered in Lexington, MA. | Health Technology |
American Society of Gene & Cell Therapy
American Society of Gene & Cell Therapy Miscellaneous Commercial ServicesCommercial Services The American Society of Gene & Cell Therapy is a medical and professional organization that represents researchers and scientists devoted to the discovery of gene and cell therapies. The American company was founded by Mark A. Kay. | Commercial Services |
Genevant Sciences Corp.
Genevant Sciences Corp. Pharmaceuticals: MajorHealth Technology Part of Roivant Sciences Ltd., Genevant Sciences Corp. operates as a Canadian biopharmaceutical company. The company is based in Burnaby, Canada. The CEO of the company is Bo Rode Hansen. | Health Technology |
